Douglas Crawford, Ph.D., is the General Manager of MBC Biolabs, Managing Partner of Mission BioCapital, a VC fund investing in life sciences startups at the seed and Series A stages. We talk about the facilities that help scientists at MBC Biolabs, how to get accepted to the labs, partners, golden tickets and stories of startups; funding hypothesis, the impact, and investment criteria to get funded. Show Notes MBC Biolabs  Mission Bay Capital - Started with a realization that nothing that is discovered in a lab at a university by itself cannot benefit a patient without a company in between. - Startups are the most efficient engines to turn an idea into something very practical and useful for society. - Experiment: If we provide a Minimum Viable Space to a scientist, could they do something catalytic to their idea or project? - In the mid 2000's, 100% of VCs in the Silicon Valley said that it is a terrible idea to start a life sciences incubator. They said a biotech incubator will be like an ICU for startups. - Biotech companies don't have market risk- They mostly have technical risk. - The startups that incubated at MBC Biolabs (since 2013) raised over $10 Billion, brought 54 programs to the clinic, 13 approved diagnostics, and 71 products to market. - Selection criteria to get accepted to MBC Biolabs. - If a scientist was lucky to be funded by a VC in the mid 2000's, she/he would have spent about 6-12 months getting their lab up and running, which was fixed by incubators like MBC Biolabs. - Incubators give an opportunity for scientists to prove themselves. - Strategic advice isn't very popular with life sciences entrepreneurs. They are mostly looking for technical validation. - Different definition of pivot. - Golden Tickets - Origin story of Mission Bay Capital- How Jack Wadsworth, Honorary Chairman of Morgan Stanley Asia and Advisory Director of Morgan Stanley globally. encouraged them to raise a fund to invest in startups Doug and his team were incubating. The fund evolved into Mission Bio Capital. - Invest in therapeutics (70%), diagnostics, medical devices, and food. - How they look at risks and insights, and how they invest. - Checkout stories of Caribou Biosciences- Jennifer Doudna & Rachel Haurwitz; Alector- Arnon Rosenthal, Ph.D. - Nitrase Therapeutics- Irene Griswold-Prenner. Story of how a whole new class of enzymes were identified - Areas of interest for investment. - Thoughts on ways the investment funds need to change. - Book recommendations: Noise, Super forecasting